Back

The remarkable story of a wonder drug, which now comes to an end in the primary prevention setting: say bye-bye to aspirin!

European Heart Journal

27 December 2018
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY BASIC SCIENCE Pharmacology and Pharmacotherapy

Contributors

Marco Valgimigli
Marco Valgimigli

Author

You may be interested in
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
6 July 2023
thumbnail
Congress Presentation
Pharmacokinetic and pharmacodynamic assessment of a lipid-based aspirin formulation: results of a prospective, randomised, crossover study
1 September 2019
thumbnail
Congress Presentation
Prevalence and characteristics of low-dose acetylsalicylic acid intake in the German population: insights from the German National Cohort (NAKO)
30 August 2026
thumbnail
Congress Presentation
Aspirin and long-Term risk of heart failure in patients with high atherosclerotic risk
20 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources